交易中 03-27 11:41:48 美东时间
-0.945
-0.81%
Brookfield Business Corporation held its annual general meeting on June 10, 2025, in a virtual format. Ten board nominees were elected, with Exchangeable Shares holding 25% voting interest and Class B Shares 75%. Full voting results are available online.
2025-06-10 21:35
Boundless Bio announces portfolio prioritization focusing on BBI-355 and BBI-825 combination therapy, and BBI-940 for its Kinesin program. The company extends its cash runway into early 2028, discontinues certain clinical trial arms, and plans to initiate new trials in 2025. A webcast on May 27 will provide further details.
2025-05-23 20:01